Compounded semaglutide: what TikTok gets right and wrong

What did @drokojie actually say?

The creator pushed back on a chief medical officer's TikTok claim that compounded semaglutide is inherently unsafe because semaglutide is patented. Their core argument: the CMO left out a critical detail. Semaglutide appeared on the FDA's drug shortage list, which legally permits licensed compounding pharmacies to produce it. "Just because drugs are coming from a compounding pharmacy doesn't necessarily make them unsafe," they said. They also argued that compounding has expanded access for people priced out of brand-name GLP-1 medications, which can run upward of $1,000 per month. The video ends with a D-minus grade for the CMO's video. The creator gets the shortage-list mechanism right. Where things get murkier is the implied safety equivalency, which deserves a harder look.

Does the science back this up?

Mostly, yes, with real caveats. The FDA's shortage-list mechanism is real and was actively used. When Wegovy and Ozempic faced documented shortages, the FDA added semaglutide to its shortage list under 21 U.S.C. 503A and 503B, permitting compounding pharmacies to produce copies. Gudeman et al. (2013, Drug Safety) documented that compounding errors cause measurable patient harm, but that research predates current 503B outsourcing facility standards, which require Current Good Manufacturing Practice compliance. A 2023 FDA analysis found that 503B outsourcing facilities operate under significantly stricter oversight than traditional 503A pharmacies. The honest answer is that quality varies dramatically depending on which type of compounding facility is involved. A PCAB-accredited 503B outsourcing facility is not the same as a small 503A compounding shop, and conflating them distorts the risk picture. The creator is right that the shortage-list permission exists. They are less precise about the range of quality within the compounding pharmacy universe.

What did they get wrong (or right)?

They got the regulatory mechanism right. The FDA shortage-list exception is real, it was publicly documented, and a basic search does confirm it. Credit where it's due. But two things deserve pushback.

First, "compounding pharmacies are compounding semaglutide" lumps together very different operations. 503B outsourcing facilities face FDA inspection and CGMP requirements. 503A pharmacies face far lighter oversight. The FDA issued multiple warning letters in 2023 and 2024 to compounders producing GLP-1 medications with quality failures, including incorrect concentrations and unsterile conditions. Calling the category broadly "not unsafe" overstates the assurance any one patient can have without knowing their specific pharmacy's credentials.

Second, the creator implies access and safety arguments fully rebut the CMO. They do not fully rebut the sourcing concern. The API (active pharmaceutical ingredient) used by some compounders originates from overseas suppliers not always subject to FDA oversight. The FDA specifically warned in 2023 that some compounders were using semaglutide salt forms (semaglutide sodium, semaglutide acetate) rather than the base compound used in approved drugs, which have no established clinical safety profile.

What should you actually know?

Here is the practical picture. The FDA shortage-list exception allowed compounding of semaglutide, but the FDA removed semaglutide from the shortage list in early 2024, meaning the legal basis for most compounding has narrowed significantly. Patients sourcing compounded semaglutide now need to ask harder questions.

• Is the pharmacy a 503B outsourcing facility or a 503A compounding pharmacy? 503B facilities face federal inspection and CGMP standards. 503A facilities do not.
• Is the API sourced from an FDA-registered facility? Ask for a certificate of analysis.
• Is the product using semaglutide base or a salt form? Salt forms lack clinical safety data in humans.
• Has the pharmacy received any FDA warning letters? This is public information.

The access argument the creator makes is legitimate and important. Brand-name GLP-1 medications remain unaffordable for a large portion of people who qualify for them clinically. Blount et al. (2023, Obesity) documented that cost is the primary barrier to GLP-1 initiation. Compounding has real public health value when done correctly. But "done correctly" requires specificity the creator's video does not fully provide.